Clarity Pharmaceuticals (ASX: CU6) — Perfil da empresa, notícias e dados financeiros
Clarity Pharmaceuticals develops theranostic radiopharmaceuticals for cancer diagnosis and treatment.
Clarity Pharmaceuticals
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation theranostic products to address the treatment and diagnosis of cancer. The company utilizes its proprietary SAR Technology platform, which binds targeted delivery molecules to copper isotopes, including copper-64 for imaging and copper-67 for therapy. Its drug pipeline targets major oncology indications such as prostate cancer, breast cancer, and neuroendocrine tumors. Key clinical programs include SAR-bisPSMA for prostate cancer diagnosis and therapy, SARTATE for neuroendocrine tumors, and SAR-Bombesin for targeted prostate cancer imaging, aiming to improve targeted cancer therapies and overcome supply chain challenges.
Resumo
Operações
Produtos e/ou serviços de Clarity Pharmaceuticals
- Prostate cancer theranostic development: The company advances its dual-targeted PSMA radiopharmaceutical candidate for identifying and treating prostate cancer, conducting clinical trials evaluating copper-64 for positron emission tomography diagnostic imaging and copper-67 for targeted beta radionuclide therapy.
- Targeted diagnostic imaging agents: The organization develops radiopharmaceutical diagnostic agents using copper-64 isotopes coupled with proprietary chelating technology, conducting clinical studies to detect primary, recurrent, and metastatic prostate cancer lesions using standard PET scanning equipment.
- Targeted therapeutic radiopharmaceuticals: The entity evaluates copper-67 radioisotope therapeutic compounds designed to deliver localized radiation directly to cancer cells expressing targeted surface receptors, focusing on advanced prostate cancer patients who have failed prior standard treatments.
- Bombesin receptor targeted radiotherapeutics: The business develops targeted radiopharmaceutical agents designed to bind gastrin-releasing peptide receptors, conducting clinical evaluation for imaging and treating prostate cancer patients whose disease expresses low or negative prostate-specific membrane antigen expression.
- Somatostatin receptor targeted theranostics: The company researches chelator-paired radioisotopes targeting somatostatin receptor subtype 2, evaluating diagnostic imaging and therapeutic efficacy in clinical trials for adult and pediatric patients diagnosed with neuroendocrine tumors and neuroblastoma.
- Bifunctional chelator technology platform: The platform utilizes proprietary macrocyclic cage structures to securely bind copper isotopes to targeted delivery molecules, preventing isotope leakage in vivo and enabling centralized manufacturing with extended shelf life for global distribution.
equipe executiva do Clarity Pharmaceuticals
- Alan John TaylorExecutive Chairman
- Michelle ParkerCEO, MD & Executive Director
- David K. GreenChief Financial Officer
- Colin David BigginChief Operating Officer
- Ellen van DamChief Scientific Officer
- Lisa SadetskayaDirector of Corporate Communications.
- Mary BennettHead of People & Culture
- Shaemus GleasonExecutive Vice President of Operations
- Othon GervasioChief Medical Officer
- Eva LengyelovaExecutive Vice President of Clinical Development
Últimas notícias sobre a Clarity Pharmaceuticals
Clarity Pharmaceuticals hits target for SECuRE trial cohort
AustraliaClarity Pharmaceuticals reports seven complete cancer responses
AustraliaClarity signs major manufacturing deal for cancer imaging
AustraliaClarity Pharmaceuticals lands manufacturing deal for Copper-64
AustraliaClarity Pharmaceuticals reaches recruitment goal for prostate cancer trial
AustraliaClarity Pharmaceuticals' SECuRE trial shows promising results
Australia
Comunicados recentes
O que a Clarity Pharmaceuticals (CU6) comunicou ao mercado, do mais recente para o mais antigo.
- SAR-bisPSMA Presentation - Drug & Device Conference
- SECuRE updateFato relevante
- Becoming a substantial holder
- CORPORATE GOVERNANCE STATEMENT
- Appendix 4G
- Annual Report to shareholders
- Ceasing to be a substantial holder
- Change in substantial holding
Principais indicadores financeiros
Resultados divulgados pela Clarity Pharmaceuticals, em AUD.
- Cap. de mercado
- 623 mi
- Receita (TTM)
- 10,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -118,9 mi | -107,1 mi | |
| 9,5 mi | -69,1 mi | -64,3 mi | |
| 11,5 mi | -44,8 mi | -42,3 mi | |
| 9,8 mi | -36,2 mi | -24,6 mi |